R&D News | pharmaphorum

News

Corxel's raises $287m for obesity drug, and other financings

Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

Hopstem maps course to bring stem cell stroke therapy to US

China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.

News

Call goes out for type 1 diabetes screening in UK

A finger-prick screening programme for type 1 diabetes should roll out in the UK, say researchers, given a disease-modifying drug is now available.

News

Data builds behind Moderna's skin cancer vaccine

Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.

Corxel's raises $287m for obesity drug, and other financings

Ovarian cancer data restores faith in Corcept's relacorilant

11 high-impact drugs to look out for in 2026

Hopstem maps course to bring stem cell stroke therapy to US

Call goes out for type 1 diabetes screening in UK

Data builds behind Moderna's skin cancer vaccine

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks